Melioidosis in aspects of epidemiology, clinic, and laboratory diagnostics

Cover Page


Cite item

Full Text

Abstract

Melioidosis is a life-threatening infection caused by Burkholderia pseudomallei, an environmental Gram-negative bacterium, inhabitant of moist soils in the tropics and subtropics. There is no licensed vaccine against melioidosis. The main routes of B. pseudomallei infection are percutaneous inoculation, inhalation, or ingestion. Individual cases of vertical, sexual, zoonotic, and nosocomial transmission of melioidosis are described. Risk factors for infection are contact with soil or water (especially during the rainy season). The age over 45, type 2 diabetes, alcoholism, liver disease, chronic lung disease, chronic renal disease, and thalassemia, as well as long-term use of steroids and immunosuppressive therapy, are the main susceptibility factors for melioidosis. Among the affected adult residents of endemic regions, 80% had one or more predisposing factors, among children — about 20%. No significant influence of concomitant diseases on the development of melioidosis in travelers was found. Less than 50% of patients had predisposing factors. The incubation period of melioidosis ranges within 1—21 days; on average, 9 days, in case of sizeable infectious dose, it can be less than one day. There is no post-infectious immunity, and reinfection can occur with a different B. pseudomallei strain after successful treatment. B. pseudomallei is a facultative intracellular pathogen that can invade and multiply inside a wide range of cells, including phagocytic. The acute form of melioidosis is characterized by pneumonia, multiple abscesses, bacteremia, and systemic sepsis. Chronic, subacute, and latent forms are also possible. Antimicrobial therapy is divided into the initial intensive phase and the subsequent eradication phase. B. pseudomallei is resistant to penicillins, first- and second-generation cephalosporins, aminoglycosides, macrolides, chloramphenicol, fluoroquinolones, tetracyclines, trimethoprim, and in some cases to co-trimoxazole, and rarely to ceftazidime. Early diagnosis and appropriate management are crucial in reducing severe complications leading to high mortality, and in preventing disease recurrences. However, there is no pathognomonic melioidosis-specific feature, and the disease is not well known to physicians and microbiologists. The results of serological tests for detection of specific antibodies are ambiguous. The bacterial load of the tested sample limits the detection of antigens. Among the accelerated methods for identifying the causative agent of melioidosis, PCR has the highest sensitivity and specificity. Automated identification using microbiological analyzers generally shows good results, but about 15% of isolates are misidentified. Time-of-flight mass spectrometry with matrix-assisted laser desorption ionization is potentially useful for rapid identification of B. pseudomallei. However, existing databases require optimization by adding the reference spectra for B. pseudomallei.

About the authors

I. B. Zakharova

Volgograd Plague Control Research Institute

Author for correspondence.
Email: zib279@gmail.com
ORCID iD: 0000-0002-7808-7658

Irina B. Zakharova - PhD (Biology), Associate Professor, Head of the Department of Microbiology, Volgograd Plague Control Research Institute.

400131, Volgograd, Golubinskaya str., 7.

Phone: +7 (844) 237-33-65

Россия

A. V. Toporkov

Volgograd Plague Control Research Institute

Email: toporkov-andreyy@rambler.ru
ORCID iD: 0000-0002-3449-4657

Andrey V.Toporkov - PhD, MD (Medicine), Associate Professor, Director of Volgograd Plague Control Research Institute.

400131, Volgograd, Golubinskaya str., 7.

Россия

D. V. Viktorov

Volgograd Plague Control Research Institute

Email: dvictorov09@gmail.com
ORCID iD: 0000-0002-2722-7948

Dmitry V. Viktorov - PhD, MD (Biology), Associate Professor, Deputy Director of Volgograd Plague Control Research Institute.

400131, Volgograd, Golubinskaya str., 7.

Россия

References

  1. Захарова И.Б., Bui T.L.A., Шпак И.М., Тетерятникова Н.Н. Мелиоидоз во Вьетнаме. Актуальные вопросы мониторинга Burkholderia pseudomallei. В кн.: Актуальные направления и перспективы Российско-Вьетнамского сотрудничества в сфере обеспечения санитарно-эпидемиологического благополучия / Под ред. А.Ю. Поповой, А.В. Топоркова. Волгоград: Издательство «Волга-Пресс», 2019. С. 70-94.
  2. Захарова И.Б., Топорков А.В., Викторов Д.В. Мелиоидоз и сап: современное состояние проблемы и актуальные вопросы эпидемиологического надзора // Журнал микробиологии, эпидемиологии и иммунобиологии. 2018. № 6. С. 103-109. doi: 10.36233/0372-9311-2018-6-103-109
  3. Илюхин В.И., Сенина Т.В. Мелиоидоз: итоги столетнего изучения, современные проблемы и зримые перспективы // Эпидемиология и инфекционные болезни. 2012. № 5. С. 41-46.
  4. Ларионов Г.М., Гавенский С.Д., Погасий Н.И. Эпидемиология и профилактика мелиоидоза. В кн.: Мелиоидоз / Под ред. Н.Г. Тихонова. Волгоград: Нижневолжское книжное издательство, 1995. 224 с.
  5. Лопастейская Я.А., Молчанова Е.В., Шаров Т.Н., Кузютина Ю.А., Захарова И.Б., Викторов Д.В., Топорков А.В. Применение времяпролетной масс-спектрометрии с матрично-активированной лазерной десорбцией/ионизацией (MALDI-ToF) для идентификации возбудителей сапа и мелиоидоза // Клиническая лабораторная диагностика. 2016. Т. 61, № 8. С. 502-507.
  6. Прохватилова Е.В., Антонов В.А., Викторов Д.В., Храпова Н.П., Ткаченко Г.А., Илюхин В.И., Захарова И.Б., Гришина М.А., Плеханова Н.Г., Новицкая И.В., Кулаков М.Я., Булатова Т.В., Корсакова И.И., Савченко С.С., Бондарева О.С., Тетерятникова Н.Н., Сенина Т.В., Лопастейская Я.А., Батурин А.А., Куликова А.С. Сравнительная оценка информативности иммунологических и молекулярно-генетических методов и средств на этапах специфической индикации возбудителя мелиоидоза // Клиническая лабораторная диагностика. 2014. № 12. С. 55-59.
  7. Тарасова Т.Д., Ряпис Л.А., Меринова Л.К., Сычева Н.М. Использование трансформации для картирования хромосомы Pseudomonas pseudomallei Трансформация бактерий на плотной среде // Журнал микробиологии, эпидемиологии и иммунобиологии. 1983. № 7. С. 8-13.
  8. Bartpho T., Wongsurawat T., Wongratanacheewin S., Talaat A.M., Karoonuthaisiri N., Sermswan R.W. Genomic islands as a marker to differentiate between clinical and environmental Burkholderia pseudomallei. PLoS One, 2012, vol. 7, no. 6: e37762. doi: 10.1371/journal.pone.0037762
  9. Bugrysheva J.V., Sue D., Gee J.E., Elrod M.G., Hoffmaster A.R., Randall L.B., Chirakul S., Tuanyok A., Schweizer H.P., Weigel L.M. Antibiotic resistance markers in Burkholderia pseudomallei strain Bp1651 identified by genome sequence analysis. Antimicrob. Agents Chemother., 2017, vol. 61, no. 6, pp. e00010—17. doi: 10.1128/AAC.00010-17
  10. Bulterys P.L., Bulterys M.A., Phommasone K., Luangraj M., Mayxay M., Kloprogge S., Miliya T., Vongsouvath M., Newton P.N., Phetsouvanh R., French C.T., Miller J.F., Turner P., Dance D.A.B. Climatic drivers of melioidosis in Laos and Cambodia: a 16year case series analysis. Lancet Planet Health., 2018, vol. 2, no. 8, pp. e334-e343. doi: 10.1016/S2542-5196(18)30172-4
  11. Chaichana P., Jenjaroen K., Amornchai P., Chumseng S., Langla S., Rongkard P., Sumonwiriya M., Jeeyapant A., Chantratita N., Teparrukkul P., Limmathurotsakul D., Day N.P.J., Wuthiekanun V., Dunachie S.J. Antibodies in melioidosis: the role of the indirect hemagglutination assay in evaluating patients and exposed populations. Am. J. Trop. Med. Hyg., 2018, vol. 99, no. 6, pp. 1378-1385. doi: 10.4269/ajtmh.17-0998
  12. Chakravorty A., Heath C.H. Melioidosis: an updated review. Aust. J. Gen. Pract., 2019, vol. 48, no. 5, pp. 327-332. doi: 10.31128/AJGP-04-18-4558
  13. Challacombe J.F., Stubben C.J., Klimko C.P., Welkos S.L., Kern S.J., Bozue J.A., Worsham P.L., Cote C.K., Wolfe D.N. Interrogation of the Burkholderia pseudomallei genome to address differential virulence among isolates. PLoS One, 2014, vol. 9, no. 12: e0122178. doi: 10.1371/journal.pone.0115951
  14. Chantratita N., Rholl D.A., Sim B., Wuthiekanun V., Limmathurotsakul D., Amornchai P., Thanwisai A., Chua H.H., Ooi W.F., Holden M.T., Day N.P., Tan P., Schweizer H.P., Peacock S.J. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc. Natl. Acad. Sci. USA, 2011, vol. 108, no. 41, pp. 17165-17170. doi: 10.1073/pnas.1111020108
  15. Chen G.B., Tuan S.H., Chen L.H., Lin W.S. Neurological melioidosis (Burkholderia pseudomallei) in a chronic psychotic patient treated with antipsychotics: a case report. Medicine (B altimore), 2018, vol. 97, no. 24: e11110. doi: 10.1097/MD.0000000000011110
  16. Cheng A.C., Currie B.J. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev., 2005, vol. 18, no. 2, pp. 383-416. doi: 10.1128/CMR.18.2.383-416.2005
  17. Cheng A.C., O'brien M., Freeman K., Lum G., Currie B.J. Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am. J. Trop. Med. Hyg., 2006, vol. 74, no. 2, pp. 330-334. doi: 10.4269/ajtmh.2006.74.330
  18. Cheng A.C., Wuthiekanun V., Limmathurotsakul D., Chierakul W., Peacock S.J. Intensity of exposure and incidence of melioidosis in Thai children. Trans. R. Soc. Trop. Med. Hyg., 2008, vol. 102, no. 1, pp. S37-S39. doi: 10.1016/S0035-9203(08)70010-5
  19. Chewapreecha C., Holden M.T., Vehkala M., Valimaki N., Yang Z., Harris S.R., Mather A.E., Tuanyok A., De Smet B., Le Hello S., Bizet C., Mayo M., Wuthiekanun V., Limmathurotsakul D., Phetsouvanh R., Spratt B.G., Corander J., Keim P., Dougan G., Dance D.A., Currie B.J., Parkhill J., Peacock S.J. Global and regional dissemination and evolution of Burkholderia pseudomallei. Nat. Microbiol., 2017, vol. 2, pp. 162-163. doi: 10.1038/nmicrobiol.2016.263
  20. Choy J.L., Mayo M., Janmaat A., Currie B.J. Animal melioidosis in Australia. Acta. Trop., 2000, vol. 74, no. 2-3, pp. 153-158. doi: 10.1016/s0001-706x(99)00065-0
  21. Cruz-Migoni A., Hautbergue G.M., Artymiuk P.J., Baker P.J., Bokori-Brown M., Chang C.T., Dickman M.J., Essex-Lopresti A., Harding S.V., Mahadi N.M., Marshall L.E., Mobbs G.W., Mohamed R., Nathan S., Ngugi S.A., Ong C., Ooi W.F., Partridge L.J., Phillips H.L., Raih M.F., Ruzheinikov S., Sarkar-Tyson M., Sedelnikova S.E., Smither S.J., Tan P., Titball R.W., Wilson S.A., Rice D.W. A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. Science, 2011, vol. 334, no. 6057, pp. 821-824. doi: 10.1126/science.1211915
  22. Cummings J.E., Slayden R.A. Transient in vivo resistance mechanisms of Burkholderia pseudomallei to Ceftazidime and molecular markers for monitoring treatment response. PLoS Negl. Trop. Dis., 2017, vol. 11, no. 1: e0005209. doi: 10.1371/journal.pntd.0005209
  23. Currie B.J., Kaestli M. Epidemiology: a global picture of melioidosis. Nature, 2016, vol. 529 (7586), pp. 290-291. doi: 10.1038/529290a
  24. Currie B.J., Price E.P., Mayo M., Kaestli M., Theobald V., Harrington I., Harrington G., Sarovich D.S. Use of whole-genome sequencing to link Burkholderia pseudomallei from air sampling to mediastinal melioidosis. Australia. Emerg. Infect. Dis., 2015, vol. 21, no. 11, pp. 2052-2054. doi: 10.3201/eid2111.141802
  25. Currie B.J., Ward L., Cheng A.C. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl. Trop. Dis., 2010, vol. 4, no. 11: e900. doi: 10.1371/journal.pntd.0000900
  26. Currie B.J. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin. Respir. Crit. Care Med., 2015, vol. 36, no. 1, pp. 111-125. doi: 10.1055/s-0034-1398389
  27. Dance D. Treatment and prophylaxis of melioidosis. Int. J. Antimicrob. Agents., 2014, vol. 43, no. 4, pp. 310-318. doi: 10.1016/j.ijantimicag.2014.01.005
  28. Dance D.A., Davis T.M., Wattanagoon Y., Chaowagul W., Saiphan P., Looareesuwan S., Wuthiekanun V., White N.J. Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. J. Infect. Dis., 1989, vol. 159, no. 4, pp. 654-660. doi: 10.1093/infdis/159.4.654
  29. Deuble M., Aquilina C., Norton R. Neurologic melioidosis. Am. J. Trop. Med. Hyg., 2013, vol. 89, no. 3, pp. 535-539. doi: 10.4269/ajtmh.12-0559
  30. Fu Z., Lin Y., Wu Q., Xia Q. Pediatric suppurative parotitis caused by Burkholderia pseudomallei. J. Venom. Anim. Toxins Incl. Trop. Dis., 2016, vol. 22: 31. doi: 10.1186/s40409-016-0086-3
  31. Hamad M.A., Austin C.R., Stewart A.L., Higgins M., Vazquez-Torres A., Voskuil M.I. Adaptation and antibiotic tolerance of anaerobic Burkholderia pseudomallei. Antimicrob. Agents Chemother., 2011, vol. 55, no. 7, pp. 3313-3323. doi: 10.1128/AAC.00953-10
  32. Hoffmaster A.R., AuCoin D., Baccam P., Baggett H.C., Baird R., Bhengsri S., Blaney D.D., Brett P.J., Brooks T.J., Brown K.A., Chantratita N., Cheng A.C., Dance D.A., Decuypere S., Defenbaugh D., Gee J.E., Houghton R., Jorakate P., Lertmemongkolchai G., Limmathurotsakul D., Merlin T.L., Mukhopadhyay C., Norton R., Peacock S.J., Rolim D.B., Simpson A.J., Steinmetz I., Stoddard R.A., Stokes M.M., Sue D., Tuanyok A., Whistler T., Wuthiekanun V. Melioidosis diagnostic workshop, 2013. Emerg. Infect. Dis., 2015, vol. 21, no. 2: e141045. doi: 10.3201/eid2102.141045
  33. Hsu C.C., Singh D., Kwan G., Deuble M., Aquilina C., Korah I., Norton R. Neuromelioidosis: craniospinal MRI findings in Burkholderia pseudomallei infection. J. Neuroimaging, 2016, vol. 26, no. 1, pp. 75-82. doi: 10.1111/jon.12282
  34. Kaestli M., Schmid M., Mayo M., Rothballer M., Harrington G., Richardson L., Hill A., Hill J., Tuanyok A., Keim P., Hartmann A., Currie B.J. Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia. Environ. Microbiol., 2012, vol. 14, no. 8, pp. 2058-2070. doi: 10.1111/j.1462-2920.2011.02671.x
  35. Le Tohic S., Montana M., Koch L., Curti C., Vanelle P. A review of melioidosis cases imported into Europe. Eur. J. Clin. Microbiol. Infect. Dis., 2019, vol. 38, no. 8, pp. 1395-1408. doi: 10.1007/s10096-019-03548-5
  36. Lim W.K., Gurdeep G.S., Norain K. Melioidosis of the head and neck. Med. J. Malaysia, 2001, vol. 56, no. 4, pp. 471-477.
  37. Limmathurotsakul D., Golding N., Dance D.A., Messina J.P., Pigott D.M., Moyes C.L., Rolim D.B., Bertherat E., Day N.P., Peacock S.J., Hay S.I. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat. Microbiol., 2016, vol. 1, no. 1 (1): 15008. doi: 10.1038/nmicrobiol.2015.8
  38. Limmathurotsakul D., Peacock S.J. Melioidosis: a clinical overview. Br. Med. Bull., 2011, vol. 99, pp. 125-139. doi: 10.1093/bmb/ldr007
  39. Lipsitz R., Garges S., Aurigemma R., Baccam P., Blaney D.D., Cheng A.C., Currie B.J., Dance D., Gee J.E., Larsen J., Limmathurotsakul D., Morrow M.G., Norton R., O'Mara E., Peacock S.J., Pesik N., Rogers L.P., Schweizer H.P., Steinmetz I., Tan G., Tan P., Wiersinga W.J., Wuthiekanun V., Smith T.L. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg. Infect. Dis., 2012, vol. 18, no. 12: e2. doi: 10.3201/eid1812.120638
  40. Lumbiganon P., Chotechuangnirun N., Kosalaraksa P., Teeratakulpisarn J. Localized melioidosis in children in Thailand: treatment and long-term outcome. J. Trop. Pediatr., 2011, vol. 57, no. 3, pp. 185-191. doi: 10.1093/tropej/fmq078
  41. McLeod C., Morris P.S., Bauert P.A., Kilburn C.J., Ward L.M., Baird R.W., Currie B.J. Clinical presentation and medical management of melioidosis in children: a 24year prospective study in the Northern Territory of Australia and review of the literature. Clin. Infect. Dis., 2015, vol. 60, no. 1, pp. 21-26. doi: 10.1093/cid/ciu733
  42. Maharjan B., Chantratita N., Vesaratchavest M., Cheng A., Wuthiekanun V., Chierakul W., Chaowagul W., Day N.P., Peacock S.J. Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse. J. Clin. Microbiol., 2005, vol. 43, no. 12, pp. 6032-6034. doi: 10.1128/JCM.43.12.6032-6034.2005
  43. Meumann E.M., Cheng A.C., Ward L., Currie B.J. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin. Infect. Dis., 2012, vol. 54, no. 3, pp. 362-369. doi: 10.1093/cid/cir808
  44. Morse L.P., Smith J., Mehta J., Ward L., Cheng A.C., Currie B.J. Osteomyelitis and septic arthritis from infection with Burkholderia pseudomallei: A 20-year prospective melioidosis study from northern Australia. J. Orthop., 2013, vol. 10, no. 2, pp. 86-91. doi: 10.1016/j.jor.2013.04.001
  45. Pitman M.C., Luck T., Marshall C.S., Anstey N.M., Ward L., Currie B.J. Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm. PLoS Negl. Trop. Dis., 2015, vol. 9, no. 3: e0003586. doi: 10.1371/journal.pntd. 0003586
  46. Podnecky N.L., Wuthiekanun V., Peacock S.J., Schweizer H.P. The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental Burkholderia pseudomallei isolates. Antimicrob. Agents Chemother., 2013, vol. 57, no. 9, pp. 4381-4386. doi: 10.1128/AAC.00660-13
  47. Pumpuang A., Chantratita N., Wikraiphat C., Saiprom N., Day N.P., Peacock S.J., Wuthiekanun V. Survival of Burkholderia pseudomallei in distilled water for 16 years. Trans. R. Soc. Trop. Med. Hyg., 2011, vol. 105, no. 10, pp. 598-600. doi: 10.1016/j.trstmh.2011.06.004
  48. Reckseidler-Zenteno S.L., DeVinney R., Woods D.E. The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect. Immun., 2005, vol. 73, no. 2, pp. 1106-1115. doi: 10.1128/IAI.73.2.1106-1115.2005
  49. Sarovich D.S., Price E.P., Webb J.R., Ward L.M., Voutsinos M.Y., Tuanyok A., Mayo M., Kaestli M., Currie B.J. Variable virulence factors in Burkholderia pseudomallei (melioidosis) associated with human disease. PLoS One, 2014, vol. 9, no. 3: e91682. doi: 10.1371/journal.pone.0091682
  50. Sarovich D.S., Ward L., Price E.P., Mayo M., Pitman M.C., Baird R.W., Currie B.J. Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare. J. Clin. Microbiol., 2014, vol. 52, no. 2, pp. 650-653. doi: 10.1128/JCM.02239-13
  51. Sim S.H., Ong C.E.L., Gan Y.H., Wang D., Koh V.W.H., Tan Y.K., Wong M.S.Y., Chew J.S.W., Ling S.F., Tan B.Z.Y., Ye A.Z., Bay P.C.K., Wong W.K., Fernandez C.J., Xie S., Jayarajah P., Tahar T., Oh P.Y., Luz S., Chien J.M.F., Tan T.T., Chai L.Y.A., Fisher D., Liu Y., Loh J.J.P., Tan G.G.Y. Melioidosis in Singapore: clinical, veterinary, and environmental perspectives. Trop. Med. Infect. Dis., 2018, vol. 3, no. 1: 31. doi: 10.3390/tropicalmed3010031
  52. Sim S.H., Yu Y., Lin C.H., Karuturi R.K., Wuthiekanun V., Tuanyok A., Chua H.H., Ong C., Paramalingam S.S., Tan G., Tang L., Lau G., Ooi E.E., Woods D., Feil E., Peacock S.J., Tan P. The core and accessory genomes of Burkholderia pseudomallei: implications for human melioidosis. PLoS Pathog., 2008, vol. 4, no. 10: e1000178. doi: 10.1371/journal.ppat.1000178
  53. Spring-Pearson S.M., Stone J.K., Doyle A., Allender C.J., Okinaka R.T., Mayo M., Broomall S.M., Hill J.M., Karavis M.A., Hubbard K.S., Insalaco J.M., McNew L.A., Rosenzweig C.N., Gibbons H.S., Currie B.J., Wagner D.M., Keim P., Tuanyok A. Pangenome analysis of Burkholderia pseudomallei: genome evolution preserves gene order despite high recombination rates. PLoS One, 2015, vol. 10, no. 10: e0140274. doi: 10.1371/journal.pone.0140274
  54. Stanton A.T., Fletcher W. Melioidosis, a disease of rodents communicable to man. Lancet, 1925, no. 205, pp. 10-13. doi: 10.1016/S0140-6736(01)04724-9
  55. Tang Y., Deng J., Zhang J., Zhong X., Qiu Y., Zhang H., Xu H. Epidemiological and clinical features of melioidosis: a report of seven cases from Southern Inland China. Am. J. Trop. Med. Hyg., 2018, vol. 98, no. 5, pp. 1296- 1299. doi: 10.4269/ajtmh.17-0128
  56. Tuanyok A., Leadem B.R., Auerbach R.K., Beckstrom-Sternberg S.M., Beckstrom-Sternberg J.S., Mayo M., Wuthiekanun V., Brettin T.S., Nierman W.C., Peacock S.J., Currie B.J., Wagner D.M., Keim P. Genomic islands from five strains of Burkholderia pseudomallei. BMC Genomics, 2008, vol. 9: 566. doi: 10.1186/1471-2164-9-566
  57. Tuanyok A., Stone J.K., Mayo M., Kaestli M., Gruendike J., Georgia S., Warrington S., Mullins T., Allender C.J., Wagner D.M., Chantratita N., Peacock S.J., Currie B.J., Keim P. The genetic and molecular basis of O-antigenic diversity in Burkholderia pseudomallei lipopolysaccharide. PLoS Negl. Trop. Dis., 2012, vol. 6, no. 1: e1453. doi: 10. 1371/journal.pntd.0001453
  58. Turner P., Kloprogge S., Miliya T., Soeng S., Tan P., Sar P., Yos P., Moore C.E., Wuthiekanun V., Limmathurotsakul D., Turner C., Day N.P., Dance D.A. A retrospective analysis of melioidosis in Cambodian children, 2009-2013. BMC Infect. Dis., 2016, vol. 16, no. 1: 688. doi: 10.1186/s12879-016-2034-9
  59. Vanaporn M., Vattanaviboon P., Thongboonkerd V., Korbsrisate S. The rpoE operon regulates heat stress response in Burkholderia pseudomallei. FEMS Microbiol. Lett., 2008, vol. 284, no. 2, pp. 191-196. doi: 10.1111/j.1574-6968.2008.01216.x
  60. Vandana K.E., Mukhopadhyay C., Tellapragada C., Kamath A., Tipre M., Bhat V., Sathiakumar N. Seroprevalence of Burk-holderia pseudomallei among adults in coastal areas in Southwestern India. PLoS Negl. Trop. Dis., 2016, vol. 10, no. 4: e0004610. doi: 10.1371/journal.pntd.0004610
  61. Viktorov D.V., Zakharova I.B., Podshivalova M.V., Kalinkina E.V., Merinova O.A., Ageeva N.P., Antonov V.A., Merinova L.K., Alekseev V.V. High-level resistance to fluoroquinolones and cephalosporins in Burkholderia pseudomallei and closely related species. Trans. R. Soc. Trop. Med. Hyg., 2008, vol. 102, no. 1, pp. S103-S110. doi: 10.1016/S0035-9203(08)70025-7
  62. Wang Y.S., Wong C.H., Kurup A. Cutaneous melioidosis and necrotizing fasciitis caused by Burkholderia pseudomallei. Emerg. Infect. Dis., 2003, vol. 9, no. 11, pp. 1484-1485. doi: 10.3201/eid0911.030370
  63. Webb J.R., Sarovich D.S., Price E.P., Ward L.M., Mayo M., Currie B.J. Burkholderia pseudomallei lipopolysaccharide genotype does not correlate with severity or outcome in melioidosis: host risk factors remain the critical determinant. Open Forum Infect. Dis., 2019, vol. 6, no. 4: ofz091. doi: 10.1093/ofid/ofz091
  64. White M.E., Hunt J., Connell C., Langdon K. Paediatric neurological melioidosis: a rehabilitation case report. Rural Remote Health, 2016, vol. 16, no. 1: 3702. doi: 10.1016/s0140-6736(03)13374-0
  65. White N.J. Melioidosis. Lancet, 2003, vol. 361, no. 9370, pp. 1715-1722. doi: 10.1016/S0140-6736(03)13374-0
  66. Whitmore A., Krishnaswami C.S. A Hitherto undescribed infective disease in Rangoon. Ind. Med. Gaz., 1912, vol. 47, no. 7, pp. 262-267.
  67. Wiersinga W.J., Virk H.S., Torres A.G., Currie B.J., Peacock S.J., Dance D.A.B., Limmathurotsakul D. Melioidosis. Nat. Rev. Dis. Primers., 2018, vol. 1, no. 4: 17107. doi: 10.1038/nrdp.2017.107
  68. Wongwandee M., Linasmita P. Central nervous system melioidosis: a systematic review of individual participant data of case reports and case series. PLoS Negl. Trop. Dis., 2019, vol. 13, no. 4: e0007320. doi: 10.1371/journal.pntd.0007320
  69. Yabuuchi E., Kosako Y., Oyaizu H., Yano I., Hotta H., Hashimoto Y., Ezaki T., Arakawa M. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol. Immunol., 1992, vol. 36, no. 12, pp. 1251-1275. doi: 10.1111/j.1348-0421.1992.tb02129.x
  70. Yabuuchi E., Wang L., Arakawa M., Yano I. Survival of Pseudomonas pseudomallei strains at 5 degrees C. Kansenshogaku Zasshi, 1993, vol. 67, no. 4, pp. 331-335. doi: 10.11150/kansenshogakuzasshi1970.67.331
  71. Yazid M.B., Fauzi M.H., Hasan H., Md Noh A.Y., Deris Z.Z. An 11-year analysis of emergency presentations of melioidosis in northeastern Malaysia. J. Immigr. Minor Health, 2017, vol. 19, no. 3, pp. 774- 777. doi: 10.1007/s10903-016-0429-8
  72. Yi H., Cho K.H., Cho Y.S., Kim K., Nierman W.C., Kim H.S. Twelve positions in a в-lactamase that can expand its substrate spectrum with a single amino acid substitution. PLoS One, 2012, vol. 7, no. 5: e37585. doi: 10.1371/journal.pone.0037585
  73. Zakharova I.B., Lopasteyskaya Y.A., Toporkov A.V., Viktorov D.V. Influence of biochemical features of Burkholderia pseudomallei strains on identification reliability by Vitek 2 System. J. Glob. Infect. Dis., 2018, vol. 10, no. 1, pp. 7-10. doi: 10.4103/jgid.jgid_39_17
  74. Zakharova I., Teteryatnikova N., Toporkov A., Viktorov D. Development of a multiplex PCR assay for the detection and differentiation of Burkholderia pseudomallei, Burkholderia mallei, Burkholderia thailandensis, and Burkholderia cepacia complex. Acta. Trop., 2017, vol. 174, pp. 1-8. doi: 10.1016/j.actatropica.2017.06.016

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Zakharova I.B., Toporkov A.V., Viktorov D.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies